NCT01415531

Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years) Who Have Stage 1 or 2 Essential Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 641 (actual)
• Sponsor: Forest Laboratories · Industry
• Sex: All
• Age: 18 Years – 54 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Nebivolol	Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
DRUG	Placebo	Dose-match placebo

Timeline

• Start date: 2011-08-01
• Primary completion: 2012-03-01
• Completion: 2012-04-01
• First posted: 2011-08-12
• Last updated: 2013-05-16
• Results posted: 2013-05-16

Locations

75 sites across 1 country: United States